Oral Anti-Cancer Therapy Drug Parity

Year: 2015

Resolution Number: 64

Action Taken: Approved as Amended

Status:

Author(s): James Randolph Hillard, MD

Sponsor: James Randolph Hillard, MD

On behalf of:

Committee: A (Medical Care Delivery)

Resolved Section(s):
RESOLVED: That MSMS support state and federal legislation, similar to that passed in a majority of states, mandating parity between intravenous medications and oral anti-cancer therapy drugs.

Fiscal Note: NULL

Resolution: View PDF for Oral Anti-Cancer Therapy Drug Parity

For More Information, Contact:

Colin Ford , Senior Director
State and Federal Government Relations
517-336-5736
cford@msms.org